[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1992014139A1 - Procede et appareil permettant d'effectuer des dosages ameliores bases sur la luminescence - Google Patents

Procede et appareil permettant d'effectuer des dosages ameliores bases sur la luminescence Download PDF

Info

Publication number
WO1992014139A1
WO1992014139A1 PCT/US1992/000992 US9200992W WO9214139A1 WO 1992014139 A1 WO1992014139 A1 WO 1992014139A1 US 9200992 W US9200992 W US 9200992W WO 9214139 A1 WO9214139 A1 WO 9214139A1
Authority
WO
WIPO (PCT)
Prior art keywords
assay
particles
recited
electrode
complex
Prior art date
Application number
PCT/US1992/000992
Other languages
English (en)
Inventor
John K. Leland
Haresh P. Shah
John H. Kenten
Jack E. Goodman
George E. Lowke
Gary F. Blackburn
Richard J. Massey
Original Assignee
Igen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igen, Inc. filed Critical Igen, Inc.
Priority to CA002103674A priority Critical patent/CA2103674C/fr
Priority to JP4506644A priority patent/JP3061416B2/ja
Priority to EP92906820A priority patent/EP0570518B1/fr
Priority to KR1019930702344A priority patent/KR100226231B1/ko
Priority to DK92906820T priority patent/DK0570518T3/da
Priority to DE69227624T priority patent/DE69227624T2/de
Priority to AU14206/92A priority patent/AU668085B2/en
Publication of WO1992014139A1 publication Critical patent/WO1992014139A1/fr
Priority to HK98115052A priority patent/HK1017970A1/xx
Priority to GR990400531T priority patent/GR3029446T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/66—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
    • G01N21/69—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence specially adapted for fluids, e.g. molten metal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6825—Nucleic acid detection involving sensors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/66—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G01N33/5438—Electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/30—Electrochemically active labels

Definitions

  • This application relates generally to methods and apparatus for conducting binding assays, more particularly to those which measure the presence of an analyte of interest by measuring luminescence emitted by one or more labeled components of the assay system. More specifically, the invention relates to precise, reproducible, accurate homogeneous or heterogeneous specific binding assays of improved sensitivity in which the luminescent component is concentrated in the assay composition and collected on the detection system before being caused to electrochemiluminescence.
  • Background of The Invention Numerous methods and systems have been developed for the detection and quantitation of analytes of interest in biochemical and biological substances. Methods and systems which are capable of measuring trace amounts of microorganisms, pharmaceuticals, hormones, viruses, antibodies, nucleic acids and other proteins are of great value to researchers and clinicians.
  • Chemiluminescent assay techniques where a sample containing an analyte of interest is mixed with a reactant labeled with a chemiluminescent label have been developed. The reactive mixture is incubated and some portion of the labeled reactant binds to the analyte. After incubation, the bound and unbound fractions of the mixture are separated and the concentration of the label in either or both fractions can be determined by chemiluminescent techniques. The level of che iluminescence determined in one or both fractions indicates the amount of analyte of interest in the biological sample.
  • Electrochemiluminescent (ECL) assay techniques are an improvement on chemiluminescent techniques. They provide a sensitive and precise measurement of the presence and concentration of an analyte of interest. In such techniques, the incubated sample is exposed to a voltammetric working electrode in order to trigger luminescence. In the proper chemical environment, such electrochemiluminescence is triggered by a voltage impressed on the working electrode at a particular time and in a particular manner. The light produced by the label is measured and indicates the presence or quantity of the analyte.
  • ECL Electrochemiluminescent
  • 4,480,042 relates to techniques employing particle reagents consisting of shell-core particles.
  • the shell contains functional groups to which compounds of biological interest can be covalently bonded, and the high refractive index of the core results in high sensitivity to light scattering measurements.
  • the technique is based upon agglutination reactions which result from the reaction of bivalent antibodies with multivalent antigens of interest to produce aggregates which can be detected and/or measured in various ways.
  • U.S. Patent No. 4,419,453 likewise relates to the use of colored latex agglutination test methods useful for detecting the presence of immunochemicals such as antibodies and immunogens.
  • U.S. Application Serial No. 539,389 (PCT published application U.S. 89/04919) teaches sensitive, specific binding assay methods based on a luminescent phenomenon wherein inert microparticulate matter is specifically bound to one of the binding reactants of the assay system.
  • the assays may be performed in a heterogeneous (one or more separation steps) assay format and may be used most advantageously in a homogeneous (nonseparation) assay format.
  • U.S. 89/04919 relates to a composition for an assay based upon a binding reaction for the measurement of luminescent phenomenon, which composition includes a plurality of suspended particles having a surface capable of binding to a component of the assay mixture.
  • it is directed to a system for detecting or quantitating an analyte of interest in a sample, which system is capable of conducting the assay methods using the assay compositions of the inventions.
  • the system includes means for inducing the label compound in the assay medium to luminesce, and means for measuring the luminescence to detect the presence of the analyte of interest in the sample.
  • U.S. 89/04919 is directed to methods for the detection of an analyte of interest in a sample, which method includes the steps of (1) forming a composition comprising (a) a sample suspected of containing an analyte of interest, (b) an assay- performance-substance selected from the group • consisting of (i) analyte of interest or analog of the analyte of interest, (ii) a binding partner of the analyte of interest or its said analog, and (iii) a re ⁇ active component capable of binding with (i) or (ii) , wherein one of said substances is linked to a label compound having a chemical moiety capable of being induced to luminesce, and (c) a plurality of suspended particles capable of specifically binding with the analyte and/or a substance defined in (b) (i) , (ii) , or (iii) ; (2) incubating the composition to form a complex which includes a particle and said label
  • Analogs of the analyte of interest which may be natural or synthetic, are compounds which have binding properties comparable to the analyte, but include compounds of higher or lower binding capability as well. Binding partners suitable for use in the present invention are well-known. Examples are antibodies, enzymes, nucleic acids, lectins, cofactors and receptors.
  • the reactive components capable of binding with the analyte or its analog and/or with a binding partner thereof may be a second antibody or a protein such as Protein A or Protein G or may be avidin or biotin or another component known in the art to enter into binding reactions.
  • the luminescence arises from electrochemiluminescence (ECL) induced by exposing the label compound, whether bound or unbound to specific binding partners, to a voltammetric working electrode.
  • ECL electrochemiluminescence
  • the ECL reactive mixture is controllably triggered to emit light by a voltage impressed on the working electrode at a particular time and in a particular manner to generate light.
  • the emission of visible light is an advantageous feature the composition or system may emit other types of electro ⁇ magnetic radiation, such as infrared or ultraviolet light, X-rays, microwaves, etc.
  • electro ⁇ magnetic radiation such as infrared or ultraviolet light, X-rays, microwaves, etc.
  • the probability of the tunneling phenomenon falls off exponentially as the distance between the two species increases.
  • the probability of the tunneling phenomenon occurring between two species is fairly high if the distance is less than 25 Angstroms (2.5 nm) but is fairly low if the distance is greater.
  • the distance of 25 A is a rule-of-thumb used by those skilled in the art but is not an absolute limitation.
  • ECL moiety "metal-containing ECL moiety” "label,” “label compound,” and “label substance,” are used interchangeably. It is within the scope of the invention for the species termed “ECL moiety,” “metal-containing ECL moiety,” “organo- metallic,” “metal chelate,” “transition metal chelate” “rare earth metal chelate,” “label compound,” “label substance” and “label” to be linked to molecules such as an analyte or an analog thereof, a binding partner of the analyte or an analog thereof, and further binding partners of such aforementioned binding partner, or a reactive component capable of binding with the analyte, an analog thereof or a binding partner as mentioned above.
  • the above-mentioned species can also be linked to a combination of one or more binding partners and/or one or more reactive components. Additionally, the aforementioned species can also be linked to an analyte or its analog bound to a binding partner, a reactive component, or a combination of one or more binding partners and/or one or more reactive components. It is also within the scope of the invention for a plurality of the aforementioned species to be bound directly, or through other molecules as discussed above, to an analyte or its analog. For purposes of brevity, these ligands are referred to as an assay-performance-substance.
  • detection and quantitation are referred to as "measurement", it being understood that quantitation may require preparation of reference compositions and calibrations.
  • collection and concentration of complex may be used interchangeably to describe the concentration of complex within the assay composition and the collection of complex at, e.g., an electrode surface.
  • Fig. 1 is a schematic drawing of a cell for performing the microparticulate-based nonseparation and separation assays of the invention.
  • Fig. 2 is a simplified diagram of a voltage control apparatus for use with the cell of Fig. 1.
  • Fig. 3 is a schematic representation of a direct incorporation PCR format using electrochemiluminescent labeled oligonucleotides and biotin electrochemiluminescent labeled oligonucleotides as primers.
  • Fig. 4 is a schematic representation of a normal PCR format using a biotinylated primer to allow the generation of biotinylated PCR PRODUCT.
  • Fig. 5 is a schematic representation of an asymmetric PRC assay format generating single-stranded biotinylated DNA for later hybridization to electrochemiluminescent labeled oligonucleotides.
  • Fig. 6 is a graph showing specificity studies of the direct incorporation of electrochemiluminescent labeled oligonucleotides into biotinylated PCR products.
  • Fig. 7 is a standard curve of directly * incorporated electrochemiluminescent label and biotinylated oligonucleotides into HPV16 PCR products.
  • Fig. 8 is a graph showing a point mutation assay for the Ha-ras oncogene.
  • Fig. 9 is a graph showing an evaluation of the specificity of electrochemiluminescent labeled probes using P 32 electrochemiluminescent labeled probes for the Aa-ras oncogene.
  • Fig. 10 is a graph showing the determination of the relative value of electrochemiluminescent label in P 32 electrochemiluminescent label for the determination of point mutations in the Ha-ras oncogene.
  • Fig. 11 is a standard curve of the rapid "no wash” hybridization assay for HPV18.
  • Fig. 12 is a schematic representation of an assay cell used to conduct assays relying upon gravitational force to cause the complex to settle.
  • Fig. 14 is a graph showing the intensity of electrochemiluminescence as a function of time in gravity cells having different heights of assay composition over the electrode, i.e., a comparison of the intensity-time relationship for two gasket thicknesses, wherein the values represented by the open circles are for a 0.015" gasket and the values represented by the darkened circles are for a 0.075" gasket.
  • Fig. 15 is a graph showing the intensity of electrochemiluminescence in gravity cells having different heights of assay composition over the electrode surface as measured in an assay for the measurement of alpha fetal protein, i.e., a comparison of cells for AFP Assay, wherein the values represented by the open circles are for a 0.015" gasket and the values represented by the darkened circles are for a 0.075" gasket.
  • Fig. 16 is a schematic representation of a sedimentation assay cell which employs an electromagnet to cause the complex to settle on the electrode surface.
  • Fig. 17 is a graph showing the relative rates of settling of microparticulate complex under the influence of a magnetic field and of gravity, respectively, i.e., a comparison of microparticulate settling times between magnetic field induced settling and gravity settling, wherein values for the magnetic field settling are represented by open circles and the values for gravity settling are represented by darkened circles.
  • Fig. 18 is a schematic representation of a collection cell including a permanent magnet.
  • Fig. 19 is a graph showing the increase in ECL intensity as a function of time in assays conducted with the cell of Fig. 18, i.e., the effect of collection time on ECL intensity.
  • Fig. 20 is a schematic representation of the lines of force in the vicinity of the electrode surface as a function of the orientation of the magnet beneath the electrode surface.
  • Fig. 21 is a schematic representation of a rotary flow cell wherein the complexes are deposited upon the surface of the electrode by centrifugation; the centrifugal method and apparatus of the invention for capturing particles; the centrifugal flow cell of the invention.
  • Fig. 22 is a schematic representation of an evanescent-wave fluorescence detection.
  • Figs. 23 and 24 show a cell and plurality of magnets for performing the magnetic microparticulate- based separation or non-separation assay method of the invention; the plurality of magnets of the magnet system imposes the field lines which are largely parallel to the plane of the electrode surface.
  • Fig. 25 is a schematic drawing of a cell for performing the microparticulate-based non-separation and separation assays of the invention; the cell employs a working electrode and plurality of magnets as in Figs. 23 and 24.
  • the invention is in a method for performing a binding assay for an analyte of interest present in a sample.
  • the steps include:
  • the complex may be collected on, e.g., an electrode surface where it is excited and induced to electrochemilumines ⁇ e, as by impressing a voltage on the electrode, or, it may be collected on a surface and be thereafter induced to fluoresce by surface excitation as described below.
  • Total-internal- reflection-fluorescence (TIRF) has been described as a surface sensitive technique for exciting and detecting fluorophoric labels and total-internal-reflection'has been used with RAMAN and infra-red absorption as another surface-sensitive technique for measuring the presence of a label.
  • Surface plasmon resonance is an optical technique which may be used according to methods of the invention to measure labels on surfaces. The invention is thus directed to methods for exciting luminescence by surface excitation techniques.
  • the invention is preferably carried out by collecting the complex in a measurement zone, i.e., on a surface at which it can be caused to luminesce
  • the invention also embraces methods wherein the complex is collected outside a measurement zone and thereafter means are brought to that zone or other steps taken to induce and measure luminescence.
  • the collection of the complex may be carried out by several different methods, including gravity settling, filtration, centrifugation and magnetic attraction of magnetically responsive particles which form part of the complex.
  • gravity settling filtration, centrifugation and magnetic attraction of magnetically responsive particles which form part of the complex.
  • filtration filtration, centrifugation and magnetic attraction of magnetically responsive particles which form part of the complex.
  • centrifugation filtration, centrifugation and magnetic attraction of magnetically responsive particles which form part of the complex.
  • an assay-performance-substance which contains a component linked to a label compound capable of being induced to electrochemiluminesce, and (iii) a plurality of suspended particles having a density greater than the balance of said composition and being capable of specifically binding with the analyte and or said assay-performance-substance;
  • While batch assays can be performed, continuous or semi-continuous assays can be performed in flow cells.
  • the solid-phase remains in the measurement cell while the solution flows through and exits the cell. If the solid-phase (e.g., 16 particles) are more dense than water, i.e., have a density greater than that of water, (more than 1.0 g/mL) the force of gravity upon the particles causes them to fall to the bottom of the cell.
  • the cell can be constructed such that the particles settle to the bottom as the fluid flows through the cell or the cell can be constructed such that the majority of the sample is contained in the cell in a columnar compartment above the working electrode of an ECL system. Sufficient dwell time in the cell must be provided to permit the particles to settle on the surface of the electrode before inducing ECL.
  • the assay composition containing suspended particles having a density greater than the balance of the assay composition may be subjected to centrifugation in order to remove the particles to a measurement zone where they are subsequently brought into contact with, e.g., an electrode to induce electrochemiluminescence or brought directly into contact with an electrode in the centrifugation step.
  • the measurement cell is provided with means to rapidly rotate the sample and sample enclosure. Centrifugal force causes the particles in the sample to move outward from the axis of rotation of the sample enclosure and to collect on the outer surface of the sample enclosure.
  • the outer surfaces of such sample enclosure may constitute the working electrode of an ECL measurement system.
  • the particles may be removed by filtration from the assay composition. In this embodiment the particles need not have a density greater than the balance of the assay composition.
  • the particles are separated from the solution and concentrated by drawing the solution through a filter, e.g. pumping and collecting the 17 particles on the surface of the filter. This surface of the filter is, for example, coated with a thin metal film which can serve as the working electrode in an ECL detection system.
  • the suspended particles are magnetically responsive, e.g. they may be paramagnetic or ferromagnetic, and are collected in a measurement zone or, preferably, directly at the surface of an electrode, by imposition of a magnetic field on the particles.
  • the measurement cell is equipped with a magnet.
  • the magnetic field of the magnet applies a force on the particles as they reside in a batch cell or as they flow through a flow cell, causing them to separate from the bulk of the solution onto the surface of the cell which is in closest proximity to the magnet. If the magnet is placed in a proper orientation and in close proximity to the working electrode of an ECL detection system the particles will concentrate on the surface of the working electrode.
  • heterogeneous and homogeneous formats for binding assays can be implemented using the methods described above to collect and concentrate the complex on the surface of an electrode.
  • a heterogeneous binding assay the complex is separated from the composition before measuring luminescence from the label.
  • homogeneous assays no separation of the bound (to the solid phase) and unbound labeled reagents is made.
  • the measured signal from the label is much greater than it would be in the absence of a collection step. The signal from the uncomplexed labeled reagents, in contrast, is not changed.
  • an in-situ separation step is included in the homogeneous binding assay procedure.
  • the assay composition i.e., sample, assay performance substance and particles have been pumped into the measurement cell and the complex captured upon the working electrode
  • a second fluid is pumped through the cell which is free of label or labeled reagents, thereby performing an in-situ wash or separation of the complex from unbound components of the assay composition.
  • This assay procedure is technically a heterogeneous binding assay.
  • the ability to perform the separation inside the measurement cell is advantageous in that it does not require additional separation apparatus and the procedure is generally much faster than external separation methods.
  • Heterogeneous binding assays are conducted using the invention by mixing the components of the assay composition and allowing them to react for a predetermined length of time.
  • the assay composition is then subjected to a separation step wherein the solution is separated from the particles.
  • Electrochemiluminescence is then measured from either the complex or the solution. Measuring the ECL from the complex after a concentration step permits measurement of analyte with better accuracy and with a lower detection limit than is possible without concentration.
  • the invention is broadly applicable to analytes of interest which are capable of entering into binding reactions. These reactions include, e.g., antigen-antibody, ligand receptor, DNA and RNA interactions, and other known reactions.
  • the invention relates to different methods and assays for qualitatively and quantitatively detecting the presence of such analytes of interest in a multicomponent sample.
  • the sample which may contain the analyte of interest may be in solid, emulsion, suspension, liquid, or gas form, may be derived from, for example, cells and cell-derived products, water, food, blood, serum, hair, sweat, urine, feces, tissue, saliva, oils, organic solvents or air.
  • the sample may further comprise, for example, water, acetonitrile, dimethyl sulfoxide, dimethyl formamide, n-methyl-pyrrolidone or alcohols or mixtures thereof.
  • Typical analytes of interest are a whole cell or surface antigen, subcellular particle, virus, prion, viroid, antibody, antigen, hapten, fatty acid, nucleic acid, protein, lipoprotein, polysac ⁇ haride, lipopolysaccharide, glycoprotein, peptide, polypeptide, cellular metabolite, hormone, pharmacological agent, synthetic organic molecule, organometallic molecule, tranquilizer, barbiturate, alkaloid, steroid, vitamin, amino acid, sugar, lectin, recombinant or derived protein, biotin, avidin, streptavidin, or inorganic 20 molecule present in the sample.
  • the analyte of interest is present at a concentration of 10 '3 molar or less, for example, as low as 10 "12 molar or lower.
  • the assay-performance-substance which is combined with the sample containing the analyte of interest contains at least one substance selected from the group consisting of (i) added analyte of interest or its analog, as defined above, (ii) a binding partner of the analyte of interest or its said analog, and (iii) a reactive component, as defined above, capable of binding with (i) or (ii) , wherein one of said substances is linked to a compound or moiety, e.g. an ECL moiety capable of being induced to luminesce.
  • a compound or moiety e.g. an ECL moiety capable of being induced to luminesce.
  • the labeled substance may be a whole cell or surface antigen, a subcellular particle, virus, prion, viroid, antibody, antigen, hapten, lipid, fatty acid, nucleic acid, polysaccharide, protein, lipoprotein, lipopolysaccharide, glycoprotein, peptide, polypeptide, cellular metabolite, hormone, pharmacological agent, tranquilizer, barbiturate, alkaloid, steroid, vitamin, amino acid, sugar, nonbiological polymer (preferably soluble) , lectin, recombinant or derived protein, synthetic organic molecule, organometallic molecule, inorganic molecule, biotin, avidin or streptavidin.
  • the reagent is an electrochemiluminescent moiety conjugated to an antibody, antigen, nucleic acid, hapten, small nucleotide sequence, oligomer, ligand, enzyme, or biotin, avidin, streptavidin, Protein A, Protein G, or complexes thereof, or other secondary binding partner capable of binding to a primary binding partner through protein interactions.
  • Analogs of the analyte of interest which can be natural or synthetic, are typically compounds which have binding properties comparable to the analyte, but can also be compounds of higher or lower binding capability.
  • the reactive component capable of binding with the analyte or its analog, and/or with a binding partner thereof, and through which the ECL moiety can be linked to the analyte is suitably a second antibody or a protein such as Protein A or Protein G, or avidin or biotin or another component known in the art to enter into binding reactions.
  • the ECL moieties are metal chelates.
  • the metal of that chelate is suitably any metal such that the metal chelate will luminesce under the electrochemical conditions which are imposed on the reaction system in question.
  • the metal of such metal chelates is, for instance, a transition metal (such as a d-block transition metal) or a rare earth metal.
  • the metal is preferably ruthenium, osmium, rhenium, iridium, rhodium, platinum, indium, palladium, molybdenum, technetium, copper, chromium or tungsten. Especially preferred are ruthenium and osmium.
  • the ligands which are linked to the metal in such chelates are usually heterocyclic or organic in nature, and play a role in determining whether or not the metal chelate is soluble in an aqueous environment or in an organic or other nonaqueous environment.
  • the ligands can be polydentate, and can be substituted.
  • Polydentate ligands include aromatic and aliphatic ligands.
  • Suitable aromatic polydentate ligands include aromatic heterocyclic ligands.
  • Preferred aromatic heterocyclic ligands are nitrogen-containing, such as, for example, bipyridyl, bipyrazyl, terpyridyl, and 22 phenanthrolyl.
  • Suitable substituents include for example, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, carboxylate, ⁇ arboxaldehyde, carboxamide, cyano, amino, hydroxy, imino, hydroxycarbonyl, aminocarbonyl, amidine, guanidinium, ureide, sulfur-containing groups, phosphorus containing groups, and the carboxylate ester of N-hydroxysuccinimide.
  • the chelate may have one or more monodentate ligands, a wide variety of which are known to the art.
  • Suitable monodentate ligands include, for example, carbon monoxide, cyanides, isocyanides, halides, and aliphatic, aromatic and' heterocyclic phosphines, amines, stilbenes, and arsines.
  • Suitable chelates are bis [(4,4'- carbomethoxy)-2,2'-bipyridine] 2-[3-(4-methyl-2,2'-bi- pyridine-4-yl)propyl]-1,3-dioxolane ruthenium (II); bis (2,2'bipyridine) [4-(butan-l-al)-4 '-methyl-2,2 '-bi ⁇ pyridine] ruthenium (II); bis (2,2'-bipyridine) [4-(4'- methyl-2,2'-bipyridine-4 * -yl)-butyric acid] ruthenium (II); tris (2,2'bipyridine) ruthenium (II); (2,2'- bipyridine) [bis-bis(l,2-diphenylphosphino)ethylene] 2- [3-(4-methyl-2,2'-bipyridine-4 '-yl)propyl]-l,3- diox
  • the function of the ECL moieties is to emit electromagnetic radiation as a result of introduction into the reaction system of electrochemical energy. In order to do this . , they must be capable of being 23 stimulated to an excited energy state and also capable of emitting electromagnetic radiation, such as a photon of light, upon descending from that excited state. While not wishing to be bound by theoretical analysis of the mechanism of the ECL moiety's participation in the electrochemiluminescent reaction, we believe that it is oxidized by the introduction of electrochemical energy into the reaction system and then, through interaction with a reductant present in the system, is converted to the excited state. This state is relatively unstable, and the metal chelate quickly descends to a more stable state.
  • the chelate gives off electromagnetic radiation, such as a photon of light, which is detectable.
  • the amount of metal chelate or other metal- containing ECL moiety incorporated in accordance with the invention will vary from system to system. Generally, the amount of such moiety utilized is that amount which is effective to result in the emission of a detectable, and if desired, quantitatable, emission of electromagnetic energy, from the aforementioned composition or system.
  • the detection and/or quantitation of an analyte of interest is typically made from a comparison of the luminescence from a sample containing an analyte of interest and an ECL moiety to the luminescence emitted by a calibration standard developed with known amounts of the analyte of interest and ECL moiety. This assumes a homogeneous format. In the heterogeneous mode, a separation as discussed previously is carried out prior to ECL analysis.
  • the identity and amount of the metal- containing ECL moiety will vary from one system to another, depending upon prevailing conditions.
  • the appropriate metal-containing ECL moiety, and 24 sufficient amount thereof to obtain the desired result can be determined empirically by those of ordinary skill in the art, once equipped with the teachings herein, without undue experimentation.
  • the particles advantageously comprise micro ⁇ particulate matter having a diameter of 0.001 to 200 ⁇ m, such as 0.05 ⁇ m to 200 ⁇ m, preferably 0.1 ⁇ m to 100 ⁇ m, most preferably 0.5 ⁇ m to 10 ⁇ m, and a surface component capable of binding to the analyte and/or one or more of the other substances defined above.
  • the microparticulate matter may be crosslinked starch, dextrans, cellulose, proteins, organic polymers, styrene copolymer such as styrene/butadiene copolymer, acrylonitrile/butadiene/ styrene copolymer, vinylacetyl acrylate copolymer, or vinyl chloride/acrylate copolymer, inert inorganic particles, chromium dioxide, oxides of iron, silica, silica mixtures, and proteinaceous matter, or mixtures thereof.
  • the particles are suspended in the ECL system.
  • the particles can be or can include magnetically responsive particles.
  • the electrolyte is a phase through which charge is carried by ions.
  • the electrolyte is in the liquid phase, and is a solution of one or more salts or other species in water, an organic liquid 25 or mixture of organic liquids, or a mixture of water and one or more organic liquids.
  • other forms of electrolyte are also useful in certain embodiments of the invention.
  • the electrolyte may be a dispersion of one or more substances in a fluid — e.g., a liquid, a vapor, or a supercritical fluid — or may be a solution of one or more substances in a solid, a vapor or supercritical fluid.
  • a fluid e.g., a liquid, a vapor, or a supercritical fluid
  • a solution of one or more substances in a solid, a vapor or supercritical fluid e.g., a liquid, a vapor, or a supercritical fluid
  • the electrolyte is suitably a solution of a salt in water.
  • the salt can be a sodium salt or a potassium salt preferably, but incorporation of other cations is also suitable in certain embodiments, as long as the cation does not interfere with the electrochemiluminescent interaction sequence.
  • the salt's anion may be a phosphate, for example, but the use of other anions is also permissible in certain embodiments of the invention —once again, as long as the selected anion does not interfere with the electrochemiluminescent interaction sequence.
  • the composition may also be nonaqueous.
  • an electrolyte comprising an organic liquid in a nonaqueous composition.
  • the nonaqueous electrolyte is also a phase through which charge is carried by ions. Normally, this means that a salt is dissolved in the organic liquid medium.
  • suitable organic liquids are acetonitrile, dimethylsulfoxide (DMSO) , dimethylformamide (DMF) , methanol, ethanol, and mixtures of two or more of the foregoing.
  • tetraalkylammonium salts such as tetrabutylammonium tetrafluoroborate, which are soluble in organic liquids can be used with them to form nonaqueous electrolytes.
  • the electrolyte is, in certain embodiments of the invention, a buffered system.
  • Phosphate buffers 26 are often advantageous. Examples are an aqueous solution of sodium phosphate/sodium chloride, and an aqueous solution of sodium phosphate/sodium fluoride.
  • a reductant typically an amine or amine moiety (of a larger molecule) which can be oxidized and spontaneously decomposed to convert it into a highly reducing species. It is believed that the amine or amine moiety is also oxidized by electrochemical energy introduced into the reaction system. The amine or amine moiety loses one electron, and then deprotonates, or rearranges itself, into a strong reducing agent. This agent interacts with the oxidized metal-containing ECL moiety and causes it to assume the excited state discussed above.
  • a reductant typically an amine or amine moiety (of a larger molecule) which can be oxidized and spontaneously decomposed to convert it into a highly reducing species. It is believed that the amine or amine moiety is also oxidized by electrochemical energy introduced into the reaction system. The amine or amine moiety loses one electron, and then deprotonates, or rearranges itself, into a strong reducing agent. This agent interacts with the oxidized metal-containing E
  • the amine or amine moiety preferably has a carbon-centered radical with an electron which can be donated from such carbon, and an alpha carbon which can then act as a proton donor during deprotonation in order to form the reductant.
  • the amine-derived reductant provides the necessary stimulus for converting the metal-containing ECL moiety to its excited state, from which detectable electromagnetic radiation is emitted.
  • a wide range of amines and corresponding amine moieties can be utilized in practicing the present invention.
  • the amine or amine moiety is chosen to suit the pH of the system which is to be electrochemiluminescently analyzed.
  • the amine or amine moiety should be compatible with the environment in which it 27 must function during analysis, i.e., compatible with an aqueous or nonaqueous environment, as the case may be. Yet another consideration is that the amine or amine moiety selected should form an amine-derived reductant under prevailing conditions which is strong enough to reduce the oxidized metal-containing ECL moiety in the system.
  • Amines (and corresponding moieties derived therefrom) which are advantageously utilized in the present invention are aliphatic amines, such as primary, secondary and tertiary alkyl amines, the alkyl groups of each having from one to three carbon atoms, as well as substituted aliphatic amines.
  • Tripropyl amine is an especially preferred amine as it leads to, comparatively speaking, a particularly high-intensity emission of electromagnetic radiation, which enhances the sensitivity and accuracy of detection and quantitation with embodiments in which it is used.
  • diamines such as hydrazine
  • polymines such as poly(ethyleneimine) .
  • Examples of other amines suitable for practicing the invention are triethanol amine, triethyl amine, 1,4-diazabicyclo- (2.2.2)-octane, 1-piperidine ethanol, 1,4-piperazine- bis-(ethane-sulfonic acid) , tri-isopropyl amine and poly(ethyleneimine) .
  • the metal-containing ECL oiety utilized in the present invention is the reaction- limiting constituent. Accordingly, it is also typical that the amine or amine moiety is provided in a stoichiometric excess with respect thereto.
  • the amine or amine moiety is employed in a concentration of 50-150 mM.
  • a concentration of 100 mM is often advantageous.
  • the upper limit on amine or amine moiety concentration is determined by the maximum solubility of the amine or 28 moiety in the environment in which it is being used, for example in water.
  • the amount of amine or amine moiety employed is that which is sufficient to effect the transformation of the oxidized metal- containing ECL moiety into its excited state so that luminescence occurs.
  • Those of ordinary skill in the art, equipped with the teachings herein, can determine empirically the amount of amine or amine moiety advantageously used for the particular system being analyzed, without undue experimentation.
  • the assays of the invention are desirably carried out in the presence of an enhancer, typically a compound of the formula
  • R is hydrogen or C n H n2+1
  • R' is C n H 2n
  • x is 0 to 70
  • n is from 1 to 20.
  • n can be from 1 to 4.
  • Specific examples are a substance available in commerce under the name Triton X-100, of the formula
  • the enhancer is generally utilized in an amount sufficient so that in its presence the desired increase in emission of electromagnetic radiation occurs. Typically, the amount is .01% to 5.0%, more specifically 0.1% to 1.0%, v/v.
  • the ECL moiety used in accordance with the present invention is induced to emit electromagnetic
  • FIG. 1 discloses an advantageous ECL apparatus, but the methods of the present invention are not limited to application in apparatus 10, but rather may be employed in other types of ECL apparatus which include a working electrode or other triggering surface to provide electrochemical energy to trigger the ECL moiety into electrochemiluminescence. While the methods of the invention can be carried out in a static or flow- through mode, apparatus 10 includes a flow-through cell, which provides distinct advantages for many types of samples including binding assay samples. Further details of apparatus for carrying out the ECL assays of the invention are disclosed in published PCT applications US 89/04854 and U.S. 90/01370.
  • Apparatus 10 includes an electrochemical cell 12, a light detection/measurement device 14, which 30 may advantageously be a photomultiplier tube (PMT) , photodiode, charge coupled device, photographic film or emulsion or the like, and a pump 16, which is advantageously a peristaltic pump, to provide for fluid transport to, through and from cell 12. Alternatively, a positive displacement pump may be used.
  • a shutter mechanism 18 is provided between cell 12 and PMT 14 and is controllably operated to open only so far as to expose PMT 14 to cell 12 during ECL measurement periods. The shutter mechanism may be closed, for example, during maintenance.
  • a lightproof housing intended to mount the various components therein and to shield PMT 14 from any external light during the ECL measurements.
  • Cell 12 itself includes a first mounting block 20 through which passes an inlet tube 22 and an outlet tube 24, which may be advantageously constructed of stainless steel.
  • Mounting block 20 has a first, outer surface 26 and a second, inner surface 28 defining one side of a sample-holding volume 30 of cell 12 in which cell 12 holds the cleaning and/or conditioning and/or measurement solutions during corresponding operations of apparatus 10.
  • Inlet and outlet tubes 22, 24 pass through mounting block 20 from outer surface 26 to inner surface 28 and open into sample-holding volume 30.
  • a second mounting block 32 advantageously constructed of stainless steel also has a first, outer surface 34 and a second, inner surface 36.
  • Second mounting block 32 is separated from first mounting block 20 by an annular spacer 38, advantageously constructed of Teflon or other non- contaminable material.
  • annular spacer 38 advantageously constructed of Teflon or other non- contaminable material.
  • outer surface 34 of mounting block 32 defines part of the second side of the sample-holding volume 30.
  • Spacer 38 has an outer portion 40 and a central
  • Mounting block 32 further has a central aperture 46 in which a window 48 is seal-fitted to define the rest of the second side of sample-holding volume 30 as a continuation of outer surface 34.
  • Window 48 is formed of a material which is substantially transparent at the wavelength of electrochemiluminescent light emitted by the ECL moiety. Window 48 is therefore advantageously formed of glass, plastic, quartz or the like.
  • Inlet tube 22 intersects sample-holding volume 30 at a first end 50 thereof adjacent to spacer 38 and outlet tube 24 intersects sample-holding volume 30 at a second end 52 thereof, adjacent spacer 38.
  • the combination of inlet tube 22, sample-holding volume 30 and outlet tube 24 thereby provides a continuous flow path for the narrow, substantially laminar flow of a solution to, through and from cell 12.
  • Arrows A and B represent the flow into and out of inlet tube 22 and outlet tube 24, respectively.
  • Mounted on inner surface 28 of first mounting block 20 is a working electrode system 54 which, in the illustrated embodiment, includes first and second working electrodes 56 and 58. In other embodiments, a single working electrode may advantageously be provided, or only electrode 56 may be a working electrode.
  • Working electrodes 56, 58 are where the elf * trochemical and ECL reactions of interest can take place.
  • Working electrodes 56, 58 are solid voltammetric electrodes and may therefore be advantageously constructed of platinum, gold, carbons or other materials which are effective for this 32 purpose.
  • Wire connectors 60, 62 connected to working electrodes 56, 58, respectively, pass out through first mounting block 20.
  • Connectors 60, 62 are both connected to a first, "working electrode” terminal 64 of a voltage control 66, illustrated in Fig. 2.
  • Voltage control 66 advantageously operates in the manner of a potentiostat to supply voltage signals to working electrodes 56, 58 and optionally to measure current flowing therefrom during an ECL measurement.
  • connectors 60, 62 may be connected to separate terminals of voltage control 66 for individual operation.
  • the potentiostat operation of voltage control 66 is further effected through a counter electrode 68 and, optionally but advantageously, a reference electrode 70.
  • mounting block 32 is made of stainless steel and counter electrode 68 consists in exposed surfaces 72, 74 of mounting block 32.
  • Counter electrode 72, 74 and working electrodes 56, 58 provide the interface to impress the potential on the solution within sample- holding volume 30 which energizes the chemical reactions and triggers electrochemiluminescence in the sample and/or provides energy for cleaning and conditioning the surfaces of cell 12.
  • Counter electrode 72, 74 is connected by a wire connector 76 to a second, "counter electrode" terminal 78 of voltage control 66.
  • Reference electrode 70 provides a reference voltage to which the voltage applied by the working electrodes 56, 58 is referred, for example, +1.2 volts versus the reference.
  • Reference electrode 70 is advantageously located in outlet tube 24 at a position 80 spaced from cell 12 and is connected through a wire connector 82 to a third "reference electrode" terminal 84 of voltage control 66. In the three electrode mode. 33 current may not flow through reference electrode 70.
  • Reference electrode 70 may be used in a three electrode mode of operation to provide a poised, known and stable voltage and is therefore advantageously constructed of silver/silver chloride (Ag/AgCl) or is a saturated calomel electrode (SCE) .
  • Voltage control 66 may be operable in a two electrode mode of operation using only working electrode 56 and electrode 58 as a counter/reference electrode. In this two electrode mode of operation, counter/reference electrode 58 is electrically connected to voltage control terminals 78 and 84 on voltage control 66. In this case, voltage control 66 operates essentially as a battery. Voltage control 66 supplies voltage signals to working and counter electrodes 56 and 58 and optionally measures the current flowing through the respective electrodes.
  • Reference electrode 70 may alternatively be a so-called "quasi-referen ⁇ e" electrode constructed of platinum, gold, stainless steel or other material, which provides a less stable voltage, yet one that is measurable with respect to the solution in contact.
  • the reference electrode 70 or 58 serves the purpose of providing a reference against which the voltage applied to working electrodes 56 is measured.
  • the poised voltage reference is currently considered to be more advantageous.
  • Voltage control 66 in its potentiostat operation controls the various electrodes by providing a known voltage at working electrodes 56, 58 with respect to reference electrode 70 while measuring the current flow between working electrodes 56, 58 and counter electrode 72, 74. Potentiostats for this purpose are well known, and the internal structure of voltage control 66 may therefore correspond to any of the conventional, commercially available potentiostats which produce the above-recited functions and so do not form a part of the present 34 invention per se.
  • apparatus 10 may alternatively be constructed without an internal voltage control 66, and may be adapted to be connected to an external potentiostat which is separately controlled for providing the required voltage signals to electrodes 56, 58, 72, 74 and 70.
  • These voltage signals applied in a specific manner as described below, provide repeatable initial conditions for the surfaces of working electrodes 56, 58 and advantageously for the surfaces of cell 12 as a whole, a feature which contributes significantly to improved precision in ECL measurements.
  • Pump 16 is advantageously positioned at outlet tube 24 to "pull" solution from a sample volume in the direction of arrow A into inlet tube 22.
  • the solution will flow through inlet tube 22, sample- holding volume 30 and outlet tube 24 past reference electrode 70 and out in the direction of arrow B.
  • pump 16 may be positioned at inlet tube 22 to "push" the solution through apparatus 10.
  • this same flow path through inlet tube 22, sample-holding volume 30 and outlet tube 24 is used for all solutions and fluids which pass through cell 12, whereby each fluid performs a hydrodynamic cleaning action in forcing the previous fluid out of cell 12.
  • Pump 16 may be controlled to suspend its operation to hold a particular solution in cell 12 for any period of time.
  • the flow-through construction of apparatus 10 permits working electrodes to be impressed with a variable voltage or to be continuously held at a preoperative potential while being continuously exposed to one or more solutions without exposing working electrodes 56, 58 (or counter and reference electrodes 72, 74, 70) to air. Exposure to air, which opens the circuit to the reference electrode 70, permits unknown. 35 random voltage fluctuations which destroy the reproducibility of surface conditions on working electrodes 56, 58.
  • the flow-through construction permits the rapid alternation between initializing steps, in which electrode system 54 is cleaned and conditioned, and measurement steps, in which one or more measurement waveforms or sweeps trigger ECL.
  • Figs. 23 and 24 schematically show a cell and magnets 27/37 which is equipped with a magnet system which advantageously imposes field lines which are largely parallel to the plane of the electrode surface 56, 58.
  • the magnet system consists of a plurality of individual permanent or electromagnets which are stacked and oriented such that the north and south poles of the magnets 27/37 alternate in the stack.
  • the individual magnets of magnets 27/37 are separated by air or any non-magnetically responsive material.
  • the arrangement as shown in Figs. 23 and 24 advantageously applies magnetic lines of force to the region above the working electrode which are nearly horizontal to the plane of the electrode. This induces an orientation of the magnetically responsive particles in which the particles lie upon the surface of the electrode and are readily accessible to the electrochemical energy supplied by the electrode; see Fig. 20.
  • the magnet system 27/37 shown in Figs. 23 and 24 also is advantageous in that the magnetic field lines do not extend a long distance from the magnet structure; see Fig. 20.
  • the magnetic field from such a magnet system is not likely, therefore, to induce permanent magnetic behavior or ferromagnetic materials near the electrode apparatus and will not severely affect the operation of a photomultiplier tube near the flow cell apparatus.
  • the apparatus depicted in Fig. 25 is as shown in Figs. 1 and 2, and is as described above with respect to Figs. 1 and 2, except that in Fig. 25, 35. 1 positioned vertically below the horizontally oriented electrode 56 or electrodes 56, 58 are a plurality of magnets 27/37 in north-south orientation as shown in Figs. 23 and 24.
  • the invention is also directed to reagent compositions.
  • the reagent compositions may be any one of the components of the assay systems of the invention, i.e., (a) electrolyte, (b) label compound containing an ECL moiety, (c) particles, including magnetically responsive particles, (d) analyte of interest or an analog of the analyte of interest, (e) a binding partner of the analyte of interest or of its analog, (f) a reactive component capable of reacting with (d) or (e) , (g) a reductant, or (h) an electrochemiluminescence-reaction enhancer.
  • the reagents may be combined with one another for convenience of use, i.e., two component, three com ⁇ ponent, and higher multiple component mixtures may be prepared, provided that the components are not reactive with one another during storage so as to impair their function in the intended assay.
  • the reagents are two-component or multicomponent mixtures which contain particles as well as one or more other components.
  • the invention is also directed to kits.
  • the kits may include vessels containing one or more of the components (a) to (h) recited above or the kits may contain vessels containing one or more reagent compositions as described above comprising mixtures of those components, all for use in the assay methods and systems of the invention.
  • the particles While a wide range of particles can be employed in the particle-based assays of the invention, generally the particles have a density of from 1.0 to 5.0 g/mL and preferably have a density of from 1.1 to 2 g/mL. Choice of the optimum density is within the skill of the art, the rate of settling in gravity- driven assays being a trade-off between the speed of the assay and the desire to create a uniform layer of complex on the electrode surface.
  • Particles having a wide range of mean diameters can also be employed. Particles having a mean diameter of from 0.001 to 200 ⁇ m such as 0.05 to 200 ⁇ m can be used; and preferably the particles have a mean diameter of from 0.01 to 10 ⁇ m.
  • the concentration can range from 1 to 10,000 ⁇ g/mL to preferably from 5 to 1000 ⁇ g/mL.
  • the density of the particles, their size and their concentration is selected such that the particles settle at a rate of at least 0.5 mm/min and preferably at a faster rate.
  • the filtration means desirably has a pore size, measured as mean diameter, from broadly 0.01 to 90% of the mean diameter of the particles and preferably from 10% to 90% of that diameter.
  • the art has described a number of magnetic particles which can be used in the assays of the invention. For example, U.S. Patent No.
  • the particles may be paramagnetic or ferromagnetic and may be coated with various materials to which binding compounds are coupled so that the magnetic particle can be used in immunoassays.
  • the magnetic particles used in the invention have a susceptibility of at least 0.001 cgs units and desirably the susceptibility is at least 0.01 cgs units.
  • the magnetic particles may have a broad range of densities, i.e.
  • the particle sizes can range from 0.001 to 200, such as 0.001 to 200 or 0.05 to 200 ⁇ m; and preferably from 0.01 to 10 ⁇ m.
  • the concentration of the particles may range broadly from 1 to 10,000 ⁇ g per mL and preferably is from 5 to 1000 ⁇ g per mL.
  • the magnetic particles which are used have a low magnetic resonance, as described for example EP 0,180,384, so that after the magnetic field is removed from the electrode surface, the particles demagnetize and can be swept out of the assay cell.
  • the density, concentration and particle size of the magnetic particles is chosen such that the settling time is at least 0.5 mm/min and desirably it is above that rate.
  • the magnet means In operation of the magnetic cell it is often desirable to remove the magnet means from the electrode surface prior to inducing electrochemiluminescence in order not to interfere with the operation of the photomultiplier tube.
  • the assay was conducted and the results are shown in Fig. 6.
  • the assay was for the presence of HPV 16 and 18 using DNA samples isolated from the cell lines SiHa and HeLa positive for both virus types and oligonucleotides specific for each virus type.
  • the primers 2PV16, 2PV18 were biotinylated and 3PV16, 3PV18 were ECL-labeled-oligonucleotides.
  • the 2/3PV16 and 2/3PV18 oligonucleotides were specific for HPV 16 and 18 respectively.
  • the resultant bead captured ECL label was analyzed for ECL using an analyzer as described in Fig. 1. The results were plotted as ECL counts for each sample primer combination.
  • Fig. 7 The resultant bead bound ECL label was analyzed for ECL using an analyzer as described in Fig. 1.
  • the ECL peak photon counts were plotted against increasing concentrations HPV 16 DNA, expressed as a ratio of viral copies to total cellular DNA copies.
  • the primers used in this analysis for HPV16 were 1PV16 (biotin label) and 2PV16 (ECL label) .
  • DNA 39 used for each PCR was maintained at a constant l ⁇ g using calf thymus DNA.
  • PCR was performed using biotinylated HRP2 with unlabeled HRPl (for probes 1T24 and ICHR) and biotinylated HRPl with unlabeled HRP2 (for probes 2T24 and 2CHR) , generating bead bound single stranded targets for hybridization.
  • the DNA samples were the normal (Placenta) Ha-ras Gene and the mutant (NIH3T3-T24) Ha-ras Gene.
  • PCR was performed as described in Fig. 8 using only biotinylated HRP2 with unlabeled HRPl (for probes 1T24 and ICHR) .
  • the probes used were: 1T24 and ICHR containing P 32 (1T24-P, 1CHR-P) as controls. With the 1T24 and ICHR containing both P 32 and ECL label to determine the effects of the ECL label.
  • the samples were washed as earlier with TEMAC.
  • the resultant bead bound P 32 was analyzed on addition of scintillation cocktail in a scintillation counter. The results were plotted as P 32 counts per second for each sample probe combination.
  • Fig. 10 An assay was conducted and the results are shown in Fig. 10. The assay was performed as described in Fig. 4. The sample was placental DNA and amplification was performed using biotinylated HRP2 with unlabeled HRPl (for probes 1T24 and ICHR) . The resultant PCR product was then sampled to give a set of samples containing differing amounts of product. These sets of samples were then hybridized with either probes 40 labeled with P 32 (1T24-P32 and 1CHR-P32) or ECL label (1T24-ECL and 1CHR-ECL) . The results form each studies were then normalized using the average peak value from each label for the 90 ⁇ l sample. These normalized figures allow a more effective comparison of signal to background and the comparative response of the two methods. The inset figure illustrates the response at the lower level of the dilution curve. The samples were handled as described earlier. (Fig. 6 and Fig. 8.)
  • Fig. 11 An assay was conducted and the results are shown in Fig. 11.
  • the PCR was performed using biotinylated 2PV18 and unlabeled 1PV18 using HeLa DNA (400 copies per cell) using the PCR format illustrated in Fig. 3.
  • the resultant PCR reaction was then hybridized with the specific probe ECL label-3PV18.
  • the hybridization mixture was then added to streptavidin coated beads and the resultant bead bound ECL label was directly analyzed for ECL using an ECL analyzer as described in Fig. 1.
  • the results were plotted as ECL counts verses HPV18 copies added to the PCR.
  • a flow-through apparatus employing three electrodes, as described in Figs, l and 2, was used.
  • ECL Label Ru(bpy) 3 2+
  • ECL Buffer 112 mM KH 2 P0 4 , 88 mM
  • the ECL measurement cycle consists of three steps: (1) preconditioning, (2) measuring, and (3) cleaning.
  • the preconditioning step involves the application of a voltage triangle wave of 0.0 V to +2.2 V to -1.0 V to +0.6 V at 2.0 V/sec.
  • the measurement step involves the application of a triangle waveform from +0.6 V to +2.8 V to +2.0 V at 1.0 V/s.
  • the cleaning step involves the application of a voltage square wave from +0.0 V to +3.0 V to -0.5 V to 0.0 V. All voltages are relative to the Ag/AgCl reference electrode.
  • Fig. 12 depict an apparatus for conducting an assay using the force of gravity.
  • the components of the apparatus include a transparent window identified by reference numeral 48, a gasket identified by reference numeral 222, a block 20 which includes an inlet 22, a working electrode 56/58, a counterelectrode 72/74 and an outlet port 24.
  • the plane of the cell block is horizontal, i.e. perpendicular to the direction of the earth's gravitational field.
  • Labeled microparticles (Dynal) in an ECL buffer are drawn to the cell by means of a peristaltic pump.
  • the pump is turned off after the particles reach the cell.
  • the microparticles in the cell chamber fall onto the working electrode surface.
  • the rate of fall of microparticles is determined to be approximately constant at 0.5 mm/min over a distance of 10 mm, as shown in Fig. 13.
  • the number of particles to settle is a function of time and rate of fall.
  • ECL intensity is proportional to the number of particles that settle on the working electrode. The number of particles that reach the surface, and therefore the ECL intensity is limited by the height of fluid sample over the working electrode.
  • Fig. 14 shows the ECL intensity as a function of deposition time for two cells of different gasket thicknesses, 0.015 and 0.075 inches, respectively. Both cells have similar rates of deposition of microparticles but the cell with a thicker gasket gives an maximum reading which is five times larger.
  • the results of an AFP (alpha fetal protein) assay is shown in Fig. 15, comparing the two cells. Again, the cell with the thicker gasket produces five times the ECL signal intensity.
  • FIG. 16 A cell for conduct of an assay using magnetic force to cause the microparticulate to settle is shown in Fig. 16.
  • Reference numeral 48 refers to a transparent window, reference numeral 122 to a gasket, reference numeral 22 to the inlet in the cell block, reference numeral 56/58 to the working electrode, reference numeral 24 to the sample outlet, reference numeral 20 to the cell block itself and reference 27 to an electromagnet.
  • the plane of the cell block is oriented horizontally.
  • Labeled microparticles (Dynal) in ECL buffer are drawn to the cell by means of a peristaltic pump. The pump is turned off after the microparticles reach the cell.
  • microparticles in the cell chamber are drawn to the working electrode by means of a magnetic field generated using electromagnet 27 44 operating at 12 volts and 1.5 amps.
  • electromagnet 27 44 operating at 12 volts and 1.5 amps.
  • the rate of deposition of microparticles is greatly increased over that observed when the microparticles settle solely due to the force of gravity. This is shown in Fig. 17.
  • EXAMPLE 3 ECL Apparatus and Method for Deposition of Microparticles. Magnetic Collection using a Collection Cell.
  • FIG. 18 An assay is carried out in a cell as described in Fig. 18.
  • reference numeral 48 refers to transparent window, reference numeral 132 to a gasket, reference numeral 22 to an inlet in the cell block, reference numeral 56/58 to a working electrode, reference numeral 20 to the cell block itself, reference numeral 24 to the sample outlet and reference numeral 37 to a permanent magnet.
  • the plane of the cell block is oriented horizontally. Labeled microparticles (Dynal) in ECL buffer are drawn to the electrochemical cell by means of a peristaltic pump.
  • permanent magnet 37 Prior to the sample introduction, permanent magnet 37 is positioned immediately below the working electrode/solution interface at a distance of 0.035 inches.
  • the microparticles deposit onto an area over the working electrode, as defined by the area of the magnet.
  • the pump is turned off and the magnetic withdrawn after the entire sample is deposited. The longer the collection time, the more particles are deposited. Increasing the concentration of particles on the working electrode results in an increased ECL intensity as shown in Fig. 19. 45
  • Microparticles 96, 96' which are attracted to a magnet 27/37, whether it be a permanent magnet or electromagnet, align with the orientation of the magnetic field 98, 98', such as in Fig. 20 which depicts magnetic fields 98 and 98', and the resultant particle arrangements 96 and 96' which are parallel (A) and perpendicular (B) to the surface of the working electrode 56/58, in the vicinity of that surface.
  • Microparticles which are magnetically responsive, non-magnetically responsive, and of a wide range of densities can advantageously be collected by filtration upon the surface of a membrane filter.
  • the particles are pumped through a portion of a filter membrane which has pore sizes which are smaller than the diameter of the particles but preferably are substantially smaller than the particle diameter and at a sufficiently high surface density such that the collection of particles will not cause blockage of the pores.
  • the filter is advantageously largely transparent such that the filter, after collection of the particles, can be placed upon the surface of a working electrode for the purpose of inducing ECL from the particles and measuring the luminescence to measure the quantity of ECL label on the particles.
  • the membrane filter having pore sizes as described above is attached or placed upon the surface of an absorbent material such 46 that capillarity or "wicking" will spontaneously draw fluids containing microparticles through the membrane filter without requiring any apparatus to induce the flow of fluid through the filter.
  • the membrane filter, having pore sizes as described above is coated with a thin film of metal or other electronically conductive material such that the surface of the membrane can serve as a working electrode in an ECL apparatus.
  • the conductive films are readily applied to the surface of a membrane by methods commonly used in the fabrication of microelectronic devices, e.g., thermal evaporation or sputtering.
  • Such a filter- electrode is readily mounted in a flow cell such that the flow-path for the fluid is through the filter- electrode. Particles in the stream are trapped by the filter-electrode and are easily washed in-situ providing for a rapid and simple means for performing heterogeneous assays without any external washing apparatus.
  • the rotary flow cell shown in Fig. 21 provides another means to capture the complex on the surface of the working electrode in order to measure luminescence.
  • the assay solution enters the apparatus via inlet 261 and is pumped into cell 262 through rotary seal 263 while a rotational motion is imparted to the cell, as indicated by arrow R.
  • the denser particles of the complex are concentrated on the surface of working electrode 264. While the cell is still rotating the solution passes out of the cell via outlet.268.
  • the light output passing through cell 47 window 267 is measured by photomultiplier tube 265.
  • the light output is directed from the vertical working electrode surface(s) 264 reflecting off curved mirror surfac (s) 266 located at the center of the cell; counter electrode(s) 269 is also shown.
  • Fig. 21 shows a centrifugal method and apparatus of the invention for capturing particles, as well as a centrifugal flow cell of the invention.
  • ECL Electrochemiluminescent
  • Electrochemiluminescence using the magnetic particles was measured using a Hamamatsu R374 photomultiplier tube centered above the flow cell where particles had concentrated on the working electrode surface.
  • Table I shows ECL photoemission levels obtained from the labeled-protein coated magnetically responsive particles.
  • ECL Electrochemiluminescent
  • Nonmagnetic Particles Uniform and nonuniform, polymeric and nonpolymeric, non-magnetical responsive particles (Aldrich, Milwaukee, WI 53201; Duke Scientific, Palo Alto, CA 94303) were coated with labeled proteins as described in Example 7. The coated particles were washed with ECL buffer three times before making 2 mL of a 300 ⁇ g/mL suspension. Using a peristaltic pump, 500 ⁇ L of the particle suspension was drawn into the flow cell. The coated particles were then concentrated onto the working electrode by gravitational means as described in Example 1. Electrochemiluminescence using the nonmagnetic particles was measured with a Hamamatsu R374 photomultiplier tube centered above the flow cell where particles had concentrated on the working electrode surface. Table II shows ECL photoemission levels obtained from the coated nonmagnetic particles. 50
  • TSH Stimulating Hormone
  • the reaction mixture was purified by passage through a Sephadex G - 25 column (I 20cm in 0.15M potassium phosphate, 0.15M NaCl with 0.05% sodium azide pH 7.2).
  • the Ru(bpy) 3 2+ -labeled mouse anti-digoxin fractions were collected and pooled.
  • the labeled protein (Reagent IV) was determined to have 12 labels per protein molecule.
  • mice anti -TSH O. ⁇ mg of mouse anti -TSH (CIBA) was labeled with Ru(bpy) 3 2+ .
  • the MAb anti TSH antibody was buffer exchanged using Centricon 30 microconcentrators
  • the reaction was terminated by the addition of 25 ⁇ L of 1M glycine and incubated for 10 minutes.
  • the reaction mixture was purified by passage through a Sephadex G - 25 column (1 X 20cm in 0.15M potassium phosphate, 0.15M NaCl with 0.05% sodium azide pH 7.2).
  • the Ru(bpy) 3 + -labeled mouse anti- TSH fractions were collected and pooled.
  • the labeled protein (Reagent V) was determined to have 14 labels per protein.
  • TSH Stimulating Hormone
  • TSH Stimulating Hormone
  • oligonucleotides were made on an Applied Biosystems automated oligonucleotide synthesizer using the ⁇ -cyanoethyl phosphora idite (1) . Oligonucleotide amino modifications to the 5' end occurred at the last coupling step, and at the 3' end by using a modified solid phase (controlled pore glass) . Clontech (San Diego CA) supplied the amino modifiers. The resulting 5* modified oligonucleotides all contain a six carbon spacer arm to the amino group designated (C6, NH2) . The 3 « modified oligonucleotides all contain a three carbon spacer to the amino group. Oligonucleotides constructed, their modifications and utility are described below.
  • Oligonucleotides for the HPV study were directed to the E6 region as previously described (2) .
  • the oligonucleotide sequences were as follows: HPV 16; 1PV16 5' (C6, NH2) TTAGTGAGTATAGACATTATTGTTATAGTT;
  • 2PV16 5* (C6, NH2) CAGT AATACACCTAATTAACAAATCACAC;
  • 3PV165' (C6, NH2) ACAACAT AGAACAGCAATACAACAAACCG;
  • oligonucleotides enable the PCR generation of various fragments; 3PV16 or 3PV18 with 2PV16 or 2PV18 respectively form a 62bp fragment; 1PV16 with 2PV16 form a lOObp fragment; 1PV18 with 2PV18 form a 103bp fragment. It will be appreciated that the 3PV16 and 3PV18 oligonucleotides can also be used as probes hybridizing to the products from the PCR reaction of 1PV16 with 2PV16 and 1PV18 with 2PV18, as well as hybridizing to the strand produced by the oligonucleotides 2PV16 and 2PV18 within the PCR.
  • Oligonucleotides for the Ha-ras point mutation assays were as follows: 60
  • HRPl 5' (C6, NH2) GCGATGACGGAATATAAGCTGGTGGTGGTG; HRP2 5' (C6, NH2) TTCTGGATCAGCTGGATGGTCAGCGCACTC;
  • ICHR 5' (C6, NH2) GGCGCCGGCGGTGTGGGCAA;
  • ICHR and 2T24 sequences without the 5* amino modification but with a 3' amino group.
  • These 3' amino modified oligonucleotides were labeled with the ECL label and used in hybridizations. The site of the mutation/mismatch is indicated by the nucleotide in bold.
  • the probes 1T24 and ICHR hybridize to the strand produced by oligonucleotide HRP2 within the PCR.
  • the probes 2T24 and 2CHR hybridize to the strand produced by oligonucleotide HRPl within the PCR.
  • JK8 5' (C6, NH2)GTCCAATCCATCTTGGCTTGTOSAAGTCTGA JK8C 5' (C6, NH2)TCAGACTTCGACAACCCAAGATGGATTGGA1C.
  • These two sequences are derived from aequorin sequences and are complementary to each other.
  • This oligonucleotide was amino modified using an amino modifier from Clontech (San Diego CA) which allows amino modifications within the sequence. JK7 was labeled using the Ru(bpy) 3 2+ -label.
  • Oligonucleotide probe for aequorin RNA generated by in vitro transcription is aequorin RNA generated by in vitro transcription
  • TRP.C04 5* (C6,NH2)GTCCGAGGCAAATGCCAATAATGG was labeled with biotin as described below.
  • the labeled oligonucleotides were further purified by HPLC on a reverse phase Vydac C-18 semiprep column with mobile phases of A) lOOmM tetraethyl- ammonium acetate pH 7.0 and B) 50% A) and 50% acetonitrile, running the gradient from 20% to 40% of B.
  • Probes ICHR and 1T24 were also labeled with 32 P using T4 polynucleotide kinase using established methods generating probes with a specific activity of 77,000 cpm/ng (5). 62
  • Dynal M 450 particles were activated with 2- fluoro-1-methylpyridinium toluene-4-sulfonate using standard procedures (6) . These activated particles were then reacted with oligonucleotides JK8 and JK8C. To lOOmg of activated Dynal particles were added 33 nmoles of oligonucleotide in 650 ⁇ l of 0.1M NaHC0 3 followed by incubation for 3 hours with mixing. The particles were blocked by the addition of ethanola ine (4mL, 0.1M).
  • the coupled particles were mixed with 0.5mg/mL single stranded salmon sperm DNA in ECL buffer, washed 4-5 times into ECL buffer and resuspended at lOmg/ L in ECL buffer containing lOO ⁇ g/mL single stranded salmon sperm DNA.
  • Dynal M 450 particles were activated with 2- fluoro-1-methylpyridinium toluene-4-sulfonate using standard procedures (6) . The activated particles were then reacted with streptavidin (Sigma Ltd) . Activated particles (50mg) were washed with 0.1M NaHC0 3 followed by the addition of streptavidin (1.5mg) and reacted overnight. The particles were blocked by the addition of ethanolamine (4mL, 0.1M).
  • the coupled particles were mixed with 0.5mg/mL single stranded salmon sperm DNA in ECL buffer, washed 4-5 times into ECL buffer and resuspended at lOmg/mL in ECL buffer containing lOO ⁇ g/mL single stranded salmon sperm DNA.
  • the streptavidin particles from Dynal M-280 also proved valuable but gave lower signals with the current assay sequence.
  • particles were 63 blocked with BSA after antigen or antibody coupling using the buffers used for passive coating.
  • the particles were filially resuspended in 29.7 mL of ECL diluent and 300 ⁇ l tRNA (lOmg/mL) to a final concentration of 10 mg/mL particles + 100 ⁇ g/mL tRNA.
  • EXAMPLE 25 Detection of Immobilized DNA on Particles by Hybridization With ECL DNA Probes.
  • the ability to detect ECL after hybridization to particles was demonstrated by the hybridization of particles coupled to JK8 and JK8C (Example 22) with Ru(bpy) 3 2+ -label oligonucleotide JK7.
  • Individual lots of particles (300 ⁇ g) in ECL buffer were mixed with 50 ⁇ l of ECL buffer containing 12.5, 6.3, 3.01, and 1.5 fmoles of labeled JK7. These mixtures were hybridized for 4 hours at 52 ⁇ C followed by washing with ImL of ECL buffer and resuspension in 830 ⁇ l of ECL buffer. These samples were analyzed as described in Example 1.
  • the probe JK7 is complementary to the JK8 sequence and not complementary to JK8C sequence.
  • RNA/DNA antibodies were coated with antibody specific for RNA/DNA antibodies (7) following standard procedures (Example 10) .
  • Specific RNA species were generated using plasmids derived from our cloned aequorin gene (8).
  • the plasmid pA5' was cut with EcoRI purified and subjected to in vitro transcription using T3 RNA polymerase generating T3-RI RNA (negative RNA) .
  • T7 RNA polymerase generating T7-Bam RNA (positive RNA) .
  • RNA species were purified by extraction with an equal volume of phenol:chloroform (50:50) followed by chloroform extraction and precipitation of the supernatant using 2.5 vols of ethanol. The amount of RNA was determined using gel electrophoresis and spectrophotometry. These methods are well established and known to those skilled in the art (9) .
  • Streptavidin was labeled with Ru(bpy) 3 2+ -label using established methods using a 25:1 molar excess of Ru(bpy) 3 2+ -label over streptavidin (Example 13) . This labeled streptavidin was purified using an iminobiotin column following established methods (10) .
  • the streptavidin was estimated to contain 10 Ru(bpy) 3 2+ -labels per streptavidin tetramer. This labeled streptavidin was then complexed with biotinylated T35, this was achieved using a one to one mix of oligonucleotide to labeled streptavidin. Specifically 20pmoles of each were mixed in a final volume of 15 ⁇ l of ECL buffer and incubated over night at 4°C to form the labeled streptavidin- oligonucleotide (SA-T35) complex.
  • SA-T35 labeled streptavidin- oligonucleotide
  • RNA samples of positive and negative RNA were hybridized to 2 ⁇ l 66 of the SA-T35 complex (one step assay) or 25ng of the biotinylated T35 (two step assay) .
  • Samples were made up to 50 ⁇ l and hybridized for 3 hours at 50°C followed by the addition of 200 ⁇ g of anti DNA/RNA antibody coated particles in 20 ⁇ l of PBS 0.1%BSA. This mixture was mixed at room temperature for 1 hour followed by two washes in ECL buffer. Samples from the hybridization with the SA-T35 complex were resuspended in 530 ⁇ l of ECL buffer and analyzed as described in Example 1.
  • Example 1 The results are presented in Table IX.
  • thermocycler conditions were as follows, for the direct incorporation HPV 18 and 16 assay, the profile was 93 ⁇ C lsec, 50°C lsec, 60°C 2min; for the Ha-ras point mutation assay 93 ⁇ C lsec, 69 ⁇ C 2min; for the non- separation HPV assay 93°C lOsec, 50°C 30sec, 60 ⁇ C 2min.
  • the cycle numbers for these PCR runs were from 30 to 40 depending on the assay and the required degree of sensitivity.
  • Fig. 3 illustrates this assay format. The results for this assay format were demonstrated with human papilloma virus samples (2,14).
  • the assay protocol was as follows; 90 ⁇ l of PCR reaction mixture was added to 600 ⁇ g of streptavidin coupled magnetic particles I, followed by incubation at room temperature for 30min. The solid phase in these samples was separated using magnetic racks, washed with 50mM NaOH, washed with hybridization buffer (0.9 M NaCl, 50mM NaP04, pH 7.7, 5mM EDTA, 0.1% w/v ficoll, 0.1% w/v polyvinylpyrrolidone, 0.1% w/v bovine serum albumin) and resuspended in hybridization buffer containing lO ⁇ g/ L of the Ru(bpy) 3 2+ - label-oligonucleotide. These samples were hybridized for 15min at 66°C.
  • the solid phase was separated using magnetic racks, washed twice with 0.9M NaCl, 50mM NaP04, pH 7.7, 5mM EDTA, washed with 3M tetramethylammonium chloride, 50mM Tris-HCl, pH 8.0, 2mM EDTA, 0.025% triton X-100 at room temperature once and at 66°C twice for 20min each.
  • the solid phase was washed with ECL buffer three times, resuspended in 530 ⁇ l ECL buffer and electrochemiluminescence detected as described in Example 1.
  • Fig. 4 illustrates this assay format. 70
  • the assays for Ha-ras PCR products using P 32 labeled probes were similar to those using Ru(bpy) 3 2+ - label except the solid phase was finally resuspended in 250 ⁇ l of ECL buffer. These suspended samples were then transferred to 5mL of scintillation fluid and counted on a Beckman LS-100C liquid scintillation counter.
  • Fig. 8 we show data from a point mutation assay for the Ha-ras oncogene.
  • the PCR was performed as illustrated in Fig. 4 using biotinylated HRP2 with unlabeled HRPl (for probes 1T24 and ICHR) and biotinylated HRPl with unlabeled HRP2 (for probes 2T24 and 2CHR) , generating bead-bound single stranded targets for hybridization.
  • the DNA samples were the normal (Placenta) Ha-ras Gene and the mutant (NIH3T3- T24) Ha-ras Gene.
  • the probes used were: 1T24 and ICHR containing P 32 (1T24-P, ICHR-P) as controls; with the 1T24 and ICHR containing both P 32 71 and Ru(bpy) 3 2+ -label to determine the effects of the Ru(bpy) 3 2+ -label.
  • the samples were washed as earlier with TEMAC.
  • the resultant bead-bound P 32 was analyzed on addition of scintillation cocktail in a scintillation counter. The results were plotted as P 32 counts per second for each sample probe combination (see Fig. 9) .
  • EXA PLE 30 DNA-PROBE ASSAY FORMAT III. Detection and Quantitation of Human Papilloma Virus PCR Products in a Non- Separation Assay.
  • the assay format described here makes use of two oligonucleotides, both of which hybridize to the same DNA strand next to each other, one probe allows capture; the other labels the complex (sandwich hybridization) .
  • This assay was demonstrated using E.coli DNA and probes specific for the trp E/D gene region.
  • the E.coli DNA was prepared following standard protocols (16) .
  • the salmon sperm control DNA was purchased from Sigma Ltd.
  • To the samples of DNA were added 14 ⁇ l of hybridization buffer (10X PBS, lOmMEDTA and 0.7%SDS), 2ng of biotin labeled TRP.C04 and 5ng of Ru(bpy) 3 2+ -label TRP.C03. These samples were made up to lOO ⁇ l with water.
  • streptavidin coated magnetic particles I can be similarly used in the fashion that the streptavidin coated magnetic particles II are used in this example.
  • Concentration of labeled complex on a detection surface can be used to increase sensitivity of assays using evanescent wave detectors.
  • Such detectors may use either optical fiber(s) or planar optical waveguide(s) 300 to carry light 310 from a light source to the fluid environment. The light is reflected through the waveguide or optical fiber by total internal reflection (TIR) 310' which occurs when an incident light beam strikes an interface between a dielectric medium of high refractive index (n ) and one of lower refractive index (n 2 ) .
  • TIR total internal reflection
  • ⁇ 0 sin ⁇ (n 2 / )
  • Fig. 22 depicts the TIR propagation in a waveguide or optical fiber.
  • the electromagnetic field is not zero outside the medium. Physical requirements of continuity across an interface require that the electromagnetic field decay exponentially as it penetrates outside the fiber or 75 waveguide into the external environment.
  • This field is called the evanescent field 320 and is capable of exciting fluorophores to fluoresce.
  • the decay rate of the evanescent field depends on the incident wavelength, refractive indices n 1 and n 2 , and the angle of incidence.
  • the evanescent field 320 decays by approximately 90% within a distance of 100 nm from the waveguide/solution interface.
  • surrounding medium 330 has a refractive index n 2 and the optical fiber(s) or waveguide(s) 300, a fractive index n,.
  • the invention can be applied to improve the sensitivity of fluorescent binding assays using optical fibers or waveguides.
  • the assay is performed using reagents labelled with fluorescent moieties. After incubation of the particles, sample and reagents, the particles are concentrated upon the surface of the waveguide or optical fiber. Because the surface area 76 of the particles is greater than the geometric area of the waveguide or optical fiber, more fluorophores can be collected in the evanescent zone surrounding the optical element. Hence, the luminescent signal from the particles will be larger and quantitation of analyte will be more sensitive, resulting in improved detection limits.
  • Reddy EP Reynolds RK
  • Santo E Barbacid M.
  • a point mutation is responsible for the acquisition of the transforming properties by the T24 humanbladder carcinoma oncogene. Nature 1982;300:149-52.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

L'invention concerne des procédés, un appareil, des réactifs et des kits permettant de préceder à un dosage par liaison pour un analyte étudié présent dans un échantillon, basé sur l'éctrochemiluminescence au niveau d'une électrode étudiée. Selon le procédé, on peut utiliser des particules des réactifs des kits, par exemple, destinées à se déposer sur la surface de l'électrode par gravité, centrifugation ou attraction magnétique. L'appareil peut comprendre un aimant destiné à générer un champ magnétique dans une région proche de l'électrode.
PCT/US1992/000992 1988-11-03 1992-02-05 Procede et appareil permettant d'effectuer des dosages ameliores bases sur la luminescence WO1992014139A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002103674A CA2103674C (fr) 1991-02-06 1992-02-05 Appareil pour essais de luminescence ameliores et methode correspondante
JP4506644A JP3061416B2 (ja) 1991-02-06 1992-02-05 改良されたルミネセンス検定の方法と装置
EP92906820A EP0570518B1 (fr) 1991-02-06 1992-02-05 Procede et appareil permettant d'effectuer des dosages ameliores bases sur la electrochemi-luminescence
KR1019930702344A KR100226231B1 (ko) 1991-02-06 1992-02-05 개선된 발광검정방법 및 장치
DK92906820T DK0570518T3 (da) 1991-02-06 1992-02-05 Fremgangsmåder og apparat til forbedrede elektrokemiluminescens-assays
DE69227624T DE69227624T2 (de) 1991-02-06 1992-02-05 Methoden und vorrichtungen zu verbesserten electrochemi-lumineszenznachweisen
AU14206/92A AU668085B2 (en) 1988-11-03 1992-02-05 Methods and apparatus for improved luminescence assays
HK98115052A HK1017970A1 (en) 1991-02-06 1998-12-23 Methods and apparatus for improved electrochemi-luminescence assays
GR990400531T GR3029446T3 (en) 1991-02-06 1999-02-18 Method of preparing a radioactive rhenium complex solution.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US827,269 1986-02-06
US65242791A 1991-02-06 1991-02-06
US652,427 1991-02-06
US82726992A 1992-02-03 1992-02-03
US82727092A 1992-02-03 1992-02-03
US827,270 1992-02-03

Publications (1)

Publication Number Publication Date
WO1992014139A1 true WO1992014139A1 (fr) 1992-08-20

Family

ID=27417877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/000992 WO1992014139A1 (fr) 1988-11-03 1992-02-05 Procede et appareil permettant d'effectuer des dosages ameliores bases sur la luminescence

Country Status (17)

Country Link
EP (3) EP0877252B1 (fr)
JP (2) JP3061416B2 (fr)
KR (1) KR100226231B1 (fr)
CN (2) CN1495425A (fr)
AT (2) ATE173542T1 (fr)
AU (1) AU668085B2 (fr)
CA (1) CA2103674C (fr)
DE (3) DE69233703T2 (fr)
DK (2) DK0877252T3 (fr)
ES (3) ES2281119T3 (fr)
GR (1) GR3029446T3 (fr)
HK (3) HK1017970A1 (fr)
IE (1) IE69060B1 (fr)
IL (1) IL100867A (fr)
NZ (1) NZ241537A (fr)
TW (1) TW316291B (fr)
WO (1) WO1992014139A1 (fr)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667919A1 (fr) * 1991-12-11 1995-08-23 Igen, Inc. Etiquette electrochimioluminescente perfectionnee destinee a des titrages par sonde d'adn
US5466416A (en) * 1993-05-14 1995-11-14 Ghaed; Ali Apparatus and methods for carrying out electrochemiluminescence test measurements
WO1996003410A1 (fr) * 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Complexes metalliques hydrophiles
US5744367A (en) * 1994-11-10 1998-04-28 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
EP0854194A2 (fr) * 1991-07-10 1998-07-22 Igen, Inc. Appareil pour dosages par luminescence ameliorés utilisant une concentration particulaire et la détection par chemiluminescence
US6066448A (en) * 1995-03-10 2000-05-23 Meso Sclae Technologies, Llc. Multi-array, multi-specific electrochemiluminescence testing
US6136268A (en) * 1999-08-17 2000-10-24 Orion Diagnostica Method for luminescence measurements
US6140045A (en) * 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US6200531B1 (en) 1998-05-11 2001-03-13 Igen International, Inc. Apparatus for carrying out electrochemiluminescence test measurements
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US6673533B1 (en) 1995-03-10 2004-01-06 Meso Scale Technologies, Llc. Multi-array multi-specific electrochemiluminescence testing
WO2006083305A2 (fr) 2004-06-23 2006-08-10 University Of Texas System Procedes et compositions pour la detection de molecules biologiques faisant appel a un complexe de deux particules
US7314711B2 (en) 1997-05-23 2008-01-01 Bioveris Corporation Assays employing electrochemiluminescent labels and electrochemiluminescence quenchers
US7553448B2 (en) 2002-06-20 2009-06-30 Bioveris Corporation Electrochemiluminescence flow cell and flow cell components
EP2186910A2 (fr) 1997-12-23 2010-05-19 Meso Scale Technologies LLC Procédés et compositions pour dosages a luminescence ameliorée utilisant des microparticules
WO2010118411A2 (fr) 2009-04-10 2010-10-14 Meso Scale Technologies, Llc. Procédés améliorés pour effectuer des dosages
US8211279B2 (en) 2005-06-03 2012-07-03 Board Of Regents Of The University Of Texas System Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode
US8372652B2 (en) 2008-05-08 2013-02-12 Board Of Regents Of The University Of Texas System Luminescent nanostructured materials for use in electrogenerated chemiluminescence
US8586378B2 (en) 2008-04-11 2013-11-19 Board Of Regents, The University Of Texas System Method and apparatus for nanoparticle electrogenerated chemiluminescence amplification
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
WO2017153336A1 (fr) 2016-03-07 2017-09-14 F. Hoffmann-La Roche Ag Détection d'anticorps anti-p53
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
WO2018141768A1 (fr) 2017-02-02 2018-08-09 Roche Diagnostics Gmbh Dosage immunologique utilisant au moins deux agents de liaison spécifiques à un analyte pegylés
WO2019201901A1 (fr) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Nouveaux anticorps anti-thymidine kinase
WO2020043868A1 (fr) 2018-08-31 2020-03-05 F. Hoffmann-La Roche Ag Thymidine kinase (tk-1) dans la détermination d'indices de pronostic pour le dlbcl
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10677695B2 (en) 2002-11-07 2020-06-09 Lsi Medience Corporation Magnetic material for collecting magnetic particles and utilization thereof
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor
WO2021013781A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag Substance p en tant que biomarqueur du sang pour le diagnostic non invasif de l'endométriose
WO2021013785A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a9 utilisée en tant que biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2021013786A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a6 en tant que biomarqueur du sang pour le diagnostic non invasif de l'endométriose
WO2021013784A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a8 utilisée en tant que biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2021013783A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a12 en tant que biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2021094409A1 (fr) 2019-11-15 2021-05-20 F. Hoffmann-La Roche Ag Dérivation d'antibiotiques de bêta-lactame pour des mesures par spectrométrie de masse dans des échantillons de patients
US11125695B2 (en) 2016-03-11 2021-09-21 Roche Diagnostics Operations, Inc. Branched-chain amines in electrochemiluminescence detection
WO2022090455A1 (fr) 2020-11-02 2022-05-05 F. Hoffmann-La Roche Ag Anticorps nucléocapsidiques du sars-cov-2
US11391733B2 (en) 2015-08-20 2022-07-19 Roche Diagnostics Operations, Inc. Particle-based immunoassay using a pegylated analyte-specific binding agent
WO2022207628A1 (fr) 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Scf comme biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2022207685A1 (fr) 2021-04-01 2022-10-06 F. Hoffmann-La Roche Ag Psp94 utilisée en tant que biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2022243210A1 (fr) 2021-05-17 2022-11-24 F. Hoffmann-La Roche Ag Sfrp4 en tant que biomarqueur sanguin pour le diagnostic non invasif de l'adénomyose
WO2023072904A1 (fr) 2021-10-26 2023-05-04 F. Hoffmann-La Roche Ag Anticorps monoclonaux spécifiques du rbd du sars-cov-2
WO2023131594A1 (fr) 2022-01-05 2023-07-13 F. Hoffmann-La Roche Ag Dérivatisation de composés dans des échantillons de patients pour la pharmacovigilance thérapeutique (tdm)
WO2023247752A1 (fr) 2022-06-23 2023-12-28 F. Hoffmann-La Roche Ag Procédé de diagnostic de l'endométriose et de classification du stade de l'endométriose
WO2024017983A1 (fr) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Protéine de type météorine (metrnl) utilisée en tant que biomarqueur (sang) pour le diagnostic du syndrome des ovaires polykystiques
WO2024017985A1 (fr) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Protéine 1 de liaison au facteur de croissance des fibroblastes (fgfbp1) utilisée en tant que biomarqueur (sanguin) pour le diagnostic du syndrome des ovaires polykystiques
WO2024017982A1 (fr) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Leukotriène a4 hydrolase (lta4h) en tant que biomarqueur (sang) pour le diagnostic du syndrome des ovaires polykystiques

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3366842B2 (ja) * 1997-08-29 2003-01-14 エーザイ株式会社 電気化学発光測定用セル
US6312896B1 (en) * 1998-09-17 2001-11-06 Igen Inaternational, Inc. Assays for measuring nucleic acid binding proteins and enzyme activities
US7063946B2 (en) * 2001-09-10 2006-06-20 Meso Scale Technologies, Llc. Methods, reagents, kits and apparatus for protein function analysis
US20030180814A1 (en) * 2002-03-21 2003-09-25 Alastair Hodges Direct immunosensor assay
US20060275841A1 (en) * 2004-12-20 2006-12-07 Martin Blankfard Assay method and apparatus with reduced sample matrix effects
US7300631B2 (en) * 2005-05-02 2007-11-27 Bioscale, Inc. Method and apparatus for detection of analyte using a flexural plate wave device and magnetic particles
WO2007148762A1 (fr) * 2006-06-22 2007-12-27 Masahiko Kuroda Procédé de détection d'un papillomavirus humain (hpv) et ensemble d'amorces et trousses de détection utilisées pour ce procédé
US11865534B2 (en) 2008-09-24 2024-01-09 First Light Diagnostics, Inc. Imaging analyzer for testing analytes
WO2012172503A1 (fr) * 2011-06-15 2012-12-20 Koninklijke Philips Electronics N.V. Traitement de composants d'échantillon biologique
WO2013099648A1 (fr) * 2011-12-28 2013-07-04 株式会社 日立ハイテクノロジーズ Dispositif d'analyse d'échantillon et procédé d'analyse d'échantillon
CA3030203A1 (fr) * 2016-09-14 2018-03-22 Philip Morris Products S.A. Systeme de generation d'aerosol et son procede de commande
DE102017114537A1 (de) * 2017-06-29 2019-01-03 Endress+Hauser Conducta Gmbh+Co. Kg Sensormembran, Sensorkappe und optischer Sensor
US11072820B2 (en) * 2017-10-19 2021-07-27 Bio-Rad Laboratories, Inc. Digital amplification assays with unconventional and/or inverse changes in photoluminescence
US12031985B2 (en) 2018-04-19 2024-07-09 First Light Diagnostics, Inc. Detection of targets
CN111351781B (zh) * 2018-12-20 2023-11-24 麦德龙生物株式会社 电化学发光分析装置和使用其分析样品的方法
CN111007593B (zh) * 2019-05-12 2022-05-13 桂林电子科技大学 基于热扩散融嵌芯毛细管光纤微小粒子输运装置
CN111693516B (zh) * 2020-05-07 2023-04-21 四川轻化工大学 一种气液相电化学发光检测装置及检测方法
CN111693515B (zh) * 2020-05-07 2022-06-17 四川轻化工大学 一种流式电化学发光实时检测装置及检测方法
CN113030068A (zh) * 2021-02-01 2021-06-25 苏州易莱生物技术有限公司 电化学发光的检测设备

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030087A1 (fr) * 1979-11-13 1981-06-10 Technicon Instruments Company Limited Procédé et dispositif d'immuno-essais et trousse pour mise en oeuvre de ce procédé
US4431919A (en) * 1980-04-10 1984-02-14 U.S. Philips Corporation Detection apparatus, particularly for use in liquid chromatography
WO1986005815A1 (fr) * 1985-03-25 1986-10-09 Genetics International Inc. Sequences d'acide nucleique liees a des materiaux sensibles a des champs magnetiques, et methodes d'analyse et appareils utilisant lesdites sequences liees
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
WO1987006706A1 (fr) * 1986-04-30 1987-11-05 Igen, Inc. Analyses electrochimiluminescentes
US5061445A (en) * 1988-11-03 1991-10-29 Igen, Inc. Apparatus for conducting measurements of electrochemiluminescent phenomena
US5068088A (en) * 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
US5093268A (en) * 1988-04-28 1992-03-03 Igen, Inc. Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75749A (en) * 1984-07-10 1990-02-09 Serono Diagnostics Ltd Electrochemical specific-binding assay of ligand with a labelled component and kit for carrying out such assay
FI844027A (fi) * 1984-10-12 1986-04-13 Labsystems Oy Immunologiskt bestaemningsfoerfarande.
EP0247796A1 (fr) * 1986-05-22 1987-12-02 Unilever Plc Procédé de dosage immunologique en phase solide
GB8620893D0 (en) * 1986-08-29 1986-10-08 Unilever Plc Assays
ATE180057T1 (de) * 1988-11-03 1999-05-15 Igen Int Inc Elektrochemilumineszente testverfahren
CA2002083C (fr) * 1988-11-03 2001-01-09 Haresh P. Shah Moyen d'accroissement de l'electrochimiluminescence

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030087A1 (fr) * 1979-11-13 1981-06-10 Technicon Instruments Company Limited Procédé et dispositif d'immuno-essais et trousse pour mise en oeuvre de ce procédé
US4431919A (en) * 1980-04-10 1984-02-14 U.S. Philips Corporation Detection apparatus, particularly for use in liquid chromatography
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
WO1986005815A1 (fr) * 1985-03-25 1986-10-09 Genetics International Inc. Sequences d'acide nucleique liees a des materiaux sensibles a des champs magnetiques, et methodes d'analyse et appareils utilisant lesdites sequences liees
WO1987006706A1 (fr) * 1986-04-30 1987-11-05 Igen, Inc. Analyses electrochimiluminescentes
US5093268A (en) * 1988-04-28 1992-03-03 Igen, Inc. Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena
US5061445A (en) * 1988-11-03 1991-10-29 Igen, Inc. Apparatus for conducting measurements of electrochemiluminescent phenomena
US5068088A (en) * 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biochem. Biophys. Res. Comm., Volume 128, No. 2, issued 30 april 1985, Y. IKARIYAMA et al., "Electrochemical luminescence-based homogeneous immunoassay", pages 987-992, see entire document. *
Clin. Chem., Volume 26, No. 6, issued 1980, M. POURFARZANEH et al., "Cortisol directly determined in serum by fluoroimmunoassay with magnetizable solid phase", pages 730-733, see entire document. *
Clin. Chem., Volume 26, No. 9, issued September 1990, R.S. KAMEL et al., "Magnetisable solid phase fluoroimmunoassay of phenytoinin in disposable test tubes", pages 1281-1284, see entire document. *
Clin. Chem., Volume 37, No. 9, issued September 1991, J.H. KENTON et al., "Rapid electrochemiluminescence assays of polymerase chain reaction products", pages 1626-1632, see entire document. *
J. Allergy and Clin. Imm., Volume 61, No. 1, issued January 1978, J.L. GUESDON et al., "Magnetic enzyme immunoassay for measuring human IGE", pages 23-27, see entire document. *
Nucleic Acids Research, Vol. 16, No. 11, issued 1988, M.S. URDEA et al., "A comparison of non-radioisotopichybridization assay methods using chemiluminescent and enzyme labeled synthetic oligodeoxyribonucleotide probes", pages 4937-4956. *

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0854194A2 (fr) * 1991-07-10 1998-07-22 Igen, Inc. Appareil pour dosages par luminescence ameliorés utilisant une concentration particulaire et la détection par chemiluminescence
EP0854194A3 (fr) * 1991-07-10 1998-08-05 Igen, Inc. Appareil pour dosages par luminescence ameliorés utilisant une concentration particulaire et la détection par chemiluminescence
EP0667919A4 (fr) * 1991-12-11 1996-01-17 Igen Inc Etiquette electrochimioluminescente perfectionnee destinee a des titrages par sonde d'adn.
EP0667919A1 (fr) * 1991-12-11 1995-08-23 Igen, Inc. Etiquette electrochimioluminescente perfectionnee destinee a des titrages par sonde d'adn
US5466416A (en) * 1993-05-14 1995-11-14 Ghaed; Ali Apparatus and methods for carrying out electrochemiluminescence test measurements
US5543112A (en) * 1993-05-14 1996-08-06 Igen, Inc. Apparatus and methods for carrying out electrochemiluminescence test measurements
US5624637A (en) * 1993-05-14 1997-04-29 Igen, Inc. Apparatus and methods for carrying out electrochemiluminescence test measurements
US5632956A (en) * 1993-05-14 1997-05-27 Igen, Inc. Apparatus and methods for carrying out electrochemiluminescence test measurements
US5700427A (en) * 1993-05-14 1997-12-23 Igen International, Inc. Apparatus for carrying out electrochemiluminescence test measurements
US5720922A (en) * 1993-05-14 1998-02-24 Igen International, Inc. Instrument incorporating electrochemiluminescent technology
US5981286A (en) * 1994-07-25 1999-11-09 Roche Diagnostics, Gmbh Hydrophilic metal complexes
WO1996003410A1 (fr) * 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Complexes metalliques hydrophiles
US6133043A (en) * 1994-11-10 2000-10-17 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
US5744367A (en) * 1994-11-10 1998-04-28 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
US6140045A (en) * 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US6090545A (en) * 1995-03-10 2000-07-18 Meso Scale Technologies, Llc. Multi-array, multi-specific electrochemiluminescence testing
US6066448A (en) * 1995-03-10 2000-05-23 Meso Sclae Technologies, Llc. Multi-array, multi-specific electrochemiluminescence testing
US7824925B2 (en) 1995-03-10 2010-11-02 Meso Scale Technology Llp Multi-array, multi-specific electrochemiluminescence testing
US8722323B2 (en) 1995-03-10 2014-05-13 Meso Scale Technologies Llp Multi-array, multi-specific electrochemiluminescence testing
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US6673533B1 (en) 1995-03-10 2004-01-06 Meso Scale Technologies, Llc. Multi-array multi-specific electrochemiluminescence testing
US7015046B2 (en) 1995-03-10 2006-03-21 Mesoscale Technologies, Llc. Multi-array, multi-specific electrochemiluminescence testing
US8541168B1 (en) 1995-03-10 2013-09-24 Jacob Wohlstadter Multi-array, multi-specific electrochemiluminescence testing
EP2284536A3 (fr) * 1996-09-17 2011-06-08 Meso Scale Technologies, LLC. Test d'électrochimioluminescence multi-réseau plurispécifique
EP2284536A2 (fr) 1996-09-17 2011-02-16 Meso Scale Technologies, LLC. Test d'électrochimioluminescence multi-réseau plurispécifique
US7314711B2 (en) 1997-05-23 2008-01-01 Bioveris Corporation Assays employing electrochemiluminescent labels and electrochemiluminescence quenchers
EP2284277A1 (fr) 1997-12-23 2011-02-16 Meso Scale Technologies, LLC Procédés et appareil pour dosages à luminescence améliorée utilisant un polymère soluble comprenent un ligand et une pluralité de marqueurs électrochimiluminescents
EP2186910A2 (fr) 1997-12-23 2010-05-19 Meso Scale Technologies LLC Procédés et compositions pour dosages a luminescence ameliorée utilisant des microparticules
US6200531B1 (en) 1998-05-11 2001-03-13 Igen International, Inc. Apparatus for carrying out electrochemiluminescence test measurements
US6136268A (en) * 1999-08-17 2000-10-24 Orion Diagnostica Method for luminescence measurements
US7553448B2 (en) 2002-06-20 2009-06-30 Bioveris Corporation Electrochemiluminescence flow cell and flow cell components
US10677695B2 (en) 2002-11-07 2020-06-09 Lsi Medience Corporation Magnetic material for collecting magnetic particles and utilization thereof
WO2006083305A2 (fr) 2004-06-23 2006-08-10 University Of Texas System Procedes et compositions pour la detection de molecules biologiques faisant appel a un complexe de deux particules
WO2006083305A3 (fr) * 2004-06-23 2007-04-05 Univ Texas Procedes et compositions pour la detection de molecules biologiques faisant appel a un complexe de deux particules
KR101076578B1 (ko) 2004-06-23 2011-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 2입자 착물을 이용한 생물학적 분자의 검출을 위한 방법 및조성물
US8188243B2 (en) 2004-06-23 2012-05-29 Board Of Regents Of The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
US9442117B2 (en) 2004-06-23 2016-09-13 Board Of Regents Of The University Of Texas System Method for the detection of biological molecules using a two particle complex
US8871917B2 (en) 2004-06-23 2014-10-28 Board Of Regents Of The University Of Texas System Compositions for the detection of biological molecules using a two particle complex
US11045120B2 (en) 2004-07-13 2021-06-29 Dexcom, Inc. Analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10993642B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10980452B2 (en) 2004-07-13 2021-04-20 Dexcom, Inc. Analyte sensor
US10932700B2 (en) 2004-07-13 2021-03-02 Dexcom, Inc. Analyte sensor
US11026605B1 (en) 2004-07-13 2021-06-08 Dexcom, Inc. Analyte sensor
US10918313B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10918315B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US11883164B2 (en) 2004-07-13 2024-01-30 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918314B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10993641B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10827956B2 (en) 2004-07-13 2020-11-10 Dexcom, Inc. Analyte sensor
US10813576B2 (en) 2004-07-13 2020-10-27 Dexcom, Inc. Analyte sensor
US10524703B2 (en) 2004-07-13 2020-01-07 Dexcom, Inc. Transcutaneous analyte sensor
US10799158B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10799159B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US11064917B2 (en) 2004-07-13 2021-07-20 Dexcom, Inc. Analyte sensor
US10722152B2 (en) 2004-07-13 2020-07-28 Dexcom, Inc. Analyte sensor
US10709362B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10709363B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10610137B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10617336B2 (en) 2005-03-10 2020-04-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10709364B2 (en) 2005-03-10 2020-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10716498B2 (en) 2005-03-10 2020-07-21 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610135B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10743801B2 (en) 2005-03-10 2020-08-18 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918318B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10925524B2 (en) 2005-03-10 2021-02-23 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11051726B2 (en) 2005-03-10 2021-07-06 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918316B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10856787B2 (en) 2005-03-10 2020-12-08 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10898114B2 (en) 2005-03-10 2021-01-26 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918317B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11000213B2 (en) 2005-03-10 2021-05-11 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8211279B2 (en) 2005-06-03 2012-07-03 Board Of Regents Of The University Of Texas System Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode
US8840774B2 (en) 2005-06-03 2014-09-23 Board Of Regents Of The University Of Texas System Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor
US9086370B2 (en) 2008-04-11 2015-07-21 Board Of Regents Of The University Of Texas System Method for nanoparticle electrogenerated chemiluminescence amplification
US8586378B2 (en) 2008-04-11 2013-11-19 Board Of Regents, The University Of Texas System Method and apparatus for nanoparticle electrogenerated chemiluminescence amplification
US9346997B2 (en) 2008-05-08 2016-05-24 Board Of Regents Of The University Of Texas System Luminescent nanostructured materials for use in electrogenerated chemiluminescence
US8815159B2 (en) 2008-05-08 2014-08-26 Board Of Regents Of The University Of Texas System Luminescent nanostructured materials for use in electrogenerated chemiluminescence
US8372652B2 (en) 2008-05-08 2013-02-12 Board Of Regents Of The University Of Texas System Luminescent nanostructured materials for use in electrogenerated chemiluminescence
EP2417455A4 (fr) * 2009-04-10 2012-10-03 Meso Scale Technologies Llc Procédés améliorés pour effectuer des dosages
EP2417455A2 (fr) * 2009-04-10 2012-02-15 Meso Scale Technologies, LLC Procédés améliorés pour effectuer des dosages
WO2010118411A2 (fr) 2009-04-10 2010-10-14 Meso Scale Technologies, Llc. Procédés améliorés pour effectuer des dosages
US11391733B2 (en) 2015-08-20 2022-07-19 Roche Diagnostics Operations, Inc. Particle-based immunoassay using a pegylated analyte-specific binding agent
WO2017153336A1 (fr) 2016-03-07 2017-09-14 F. Hoffmann-La Roche Ag Détection d'anticorps anti-p53
US11971407B2 (en) 2016-03-07 2024-04-30 Roche Diagnostics Operations, Inc. Detection of anti-p53 antibodies
US11125695B2 (en) 2016-03-11 2021-09-21 Roche Diagnostics Operations, Inc. Branched-chain amines in electrochemiluminescence detection
US11099180B2 (en) 2017-02-02 2021-08-24 Roche Diagnostics Operations, Inc. Immunoassay using at least two pegylated analyte-specific binding agents
WO2018141768A1 (fr) 2017-02-02 2018-08-09 Roche Diagnostics Gmbh Dosage immunologique utilisant au moins deux agents de liaison spécifiques à un analyte pegylés
US12077600B2 (en) 2018-04-18 2024-09-03 Roche Diagnostics Operations, Inc. Anti-thymidine kinase antibodies
WO2019201901A1 (fr) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Nouveaux anticorps anti-thymidine kinase
WO2020043868A1 (fr) 2018-08-31 2020-03-05 F. Hoffmann-La Roche Ag Thymidine kinase (tk-1) dans la détermination d'indices de pronostic pour le dlbcl
WO2021013781A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag Substance p en tant que biomarqueur du sang pour le diagnostic non invasif de l'endométriose
WO2021013785A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a9 utilisée en tant que biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2021013786A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a6 en tant que biomarqueur du sang pour le diagnostic non invasif de l'endométriose
WO2021013784A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a8 utilisée en tant que biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2021013783A1 (fr) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a12 en tant que biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2021094409A1 (fr) 2019-11-15 2021-05-20 F. Hoffmann-La Roche Ag Dérivation d'antibiotiques de bêta-lactame pour des mesures par spectrométrie de masse dans des échantillons de patients
WO2022090455A1 (fr) 2020-11-02 2022-05-05 F. Hoffmann-La Roche Ag Anticorps nucléocapsidiques du sars-cov-2
WO2022207628A1 (fr) 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Scf comme biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2022207685A1 (fr) 2021-04-01 2022-10-06 F. Hoffmann-La Roche Ag Psp94 utilisée en tant que biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
WO2022243210A1 (fr) 2021-05-17 2022-11-24 F. Hoffmann-La Roche Ag Sfrp4 en tant que biomarqueur sanguin pour le diagnostic non invasif de l'adénomyose
WO2023072904A1 (fr) 2021-10-26 2023-05-04 F. Hoffmann-La Roche Ag Anticorps monoclonaux spécifiques du rbd du sars-cov-2
WO2023131594A1 (fr) 2022-01-05 2023-07-13 F. Hoffmann-La Roche Ag Dérivatisation de composés dans des échantillons de patients pour la pharmacovigilance thérapeutique (tdm)
WO2023247752A1 (fr) 2022-06-23 2023-12-28 F. Hoffmann-La Roche Ag Procédé de diagnostic de l'endométriose et de classification du stade de l'endométriose
WO2024017983A1 (fr) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Protéine de type météorine (metrnl) utilisée en tant que biomarqueur (sang) pour le diagnostic du syndrome des ovaires polykystiques
WO2024017985A1 (fr) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Protéine 1 de liaison au facteur de croissance des fibroblastes (fgfbp1) utilisée en tant que biomarqueur (sanguin) pour le diagnostic du syndrome des ovaires polykystiques
WO2024017982A1 (fr) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Leukotriène a4 hydrolase (lta4h) en tant que biomarqueur (sang) pour le diagnostic du syndrome des ovaires polykystiques

Also Published As

Publication number Publication date
IE920380A1 (en) 1992-08-12
DK0877252T3 (da) 2007-05-07
JP3061416B2 (ja) 2000-07-10
ES2291407T3 (es) 2008-03-01
ES2281119T3 (es) 2007-09-16
GR3029446T3 (en) 1999-05-28
ATE173542T1 (de) 1998-12-15
DE69233703D1 (de) 2007-09-06
HK1017970A1 (en) 1999-12-03
EP0570518A4 (en) 1994-05-18
EP1286164A3 (fr) 2003-10-22
ES2126591T3 (es) 1999-04-01
CN1094593C (zh) 2002-11-20
IL100867A0 (en) 1992-11-15
EP1286164A2 (fr) 2003-02-26
NZ241537A (en) 1993-06-25
JP3182515B2 (ja) 2001-07-03
HK1015878A1 (en) 1999-10-22
CA2103674C (fr) 2002-04-09
DE69233675D1 (de) 2007-02-22
AU668085B2 (en) 1996-04-26
DE69233703T2 (de) 2008-05-29
JPH11148901A (ja) 1999-06-02
JPH06509412A (ja) 1994-10-20
AU1420692A (en) 1992-09-07
HK1066059A1 (en) 2005-03-11
EP0570518A1 (fr) 1993-11-24
TW316291B (fr) 1997-09-21
CN1495425A (zh) 2004-05-12
DK0570518T3 (da) 1999-08-02
IE69060B1 (en) 1996-08-07
EP0570518B1 (fr) 1998-11-18
DE69233675T2 (de) 2007-11-15
KR100226231B1 (ko) 1999-10-15
EP0877252B1 (fr) 2007-01-10
CN1064945A (zh) 1992-09-30
DE69227624D1 (de) 1998-12-24
EP0877252A3 (fr) 1999-02-17
EP0877252A2 (fr) 1998-11-11
IL100867A (en) 1995-12-08
EP1286164B1 (fr) 2007-07-25
ATE368224T1 (de) 2007-08-15
CA2103674A1 (fr) 1992-08-07
DE69227624T2 (de) 1999-07-08

Similar Documents

Publication Publication Date Title
CA2103674C (fr) Appareil pour essais de luminescence ameliores et methode correspondante
US6078782A (en) Methods for improved particle electrochemiluminescence assays
US6325973B1 (en) Methods and apparatus for improved luminescence assays
US5779976A (en) Apparatus for improved luminescence assays
US5705402A (en) Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
US5962218A (en) Methods and apparatus for improved luminescence assays
WO1992014138A1 (fr) Procede et dispositif d'analyse utilisant la luminescence magnetique basee sur des microparticules magnetiques et comprenant une pluralite d'aimants
US5746974A (en) Apparatus for improved luminescence assays using particle concentration, electrochemical generation of chemiluminescence and chemiluminescence detection
EP0594766B1 (fr) Methodes pour dosages par luminescence ameliores utilisant une concentration particulaire et la detection par chimioluminescence
US5770459A (en) Methods and apparatus for improved luminescence assays using particle concentration, electrochemical generation of chemiluminescence detection
US6881589B1 (en) Electrochemiluminescent localizable complexes for assay compositions
US7462322B2 (en) Methods and apparatus for improved luminescence assays
AU676665C (en) Methods and apparatus for improved luminescence assays usingparticle concentration and chemiluminescence detection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2103674

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019930702344

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1992906820

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992906820

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1992906820

Country of ref document: EP